EssentialFRCS

Breast surgery

Major Clinical Specialty Areas · 29 questions · 1 free to try

Triple assessment and biopsy classification, early and locally advanced breast cancer surgery, axillary management, adjuvant and neoadjuvant therapy, familial breast cancer, ductal carcinoma in situ, benign breast disease, breast infection, reconstruction and the breast screening programme.

Every question in this topic is a single best answer item in the style of the exam, followed by an explanation that gives the reasoning for the correct option, why each distractor is wrong, a key point to carry into the exam and, where one applies, the guideline or trial it rests on. Practice mode lets you work through the topic on its own or mixed with others; exam mode draws it into timed papers.

Sample question from this topic

A 48-year-old woman is referred to the breast clinic with a lump she found three weeks ago. She is well, takes no hormonal medication, and has no family history of breast cancer. Examination confirms a 2 cm firm, mobile, non-tender lump in the upper outer quadrant of the left breast with no skin or nipple changes and no palpable axillary nodes. She asks the clinic doctor what will happen today. Which best describes the correct diagnostic approach?

  1. AClinical examination alone, with reassurance if the lump feels benign
  2. BMammography with ultrasound, with biopsy only if she requests it
  3. CFine needle aspiration cytology as the sole tissue sampling method, regardless of the imaging findings
  4. DTriple assessment: clinical examination, appropriate imaging, and needle core biopsy of the lesion
  5. EImmediate excision biopsy of the lump without prior imaging
Show answer and explanation

Correct answer: D

Every discrete breast lump is evaluated by triple assessment in a one-stop clinic: clinical examination, imaging — mammography plus targeted ultrasound in women around 40 and over, ultrasound alone as first-line in younger women with denser tissue — and pathological sampling, now by needle core biopsy, which provides histology, distinguishes in-situ from invasive disease, and yields receptor status. The strength of triple assessment lies in concordance: when all three modalities agree the lesion is benign, malignancy is excluded with very high reliability; any discordance mandates further sampling or excision. Each component alone has a meaningful false-negative rate — the combination is the safeguard.

Why the others are wrong: A — clinical impression alone misses a significant proportion of cancers; palpably 'benign' cancers are well described. B — imaging without tissue diagnosis leaves a solid lesion uncharacterised, and the decision to biopsy is clinical, not the patient's to request. C — cytology cannot distinguish invasive cancer from in-situ disease and gives no receptor information; core biopsy has replaced it for solid lesions in UK practice. E — surgical excision without prior triple assessment subjects patients to unnecessary operations for benign disease and compromises planning when cancer is found.

Key point: A discrete breast lump requires triple assessment — examination, age-appropriate imaging and core biopsy — with concordance between all three components the basis for safe diagnosis.

Guidelines: NICE suspected cancer guidance (NG12): two-week-wait referral for a woman ≥30 with an unexplained breast lump; Association of Breast Surgery standards: triple assessment (examination, imaging, needle biopsy) at a one-stop clinic.

Practise breast surgery questions

A free account includes questions from every part of the syllabus, including 1 from this topic. Subscribe for all 29 in this topic and the rest of the bank.

Create your free account

Other topics in Major Clinical Specialty Areas